PulseAI Ltd.

PulseAI Ltd. , based in Ireland, specializes in advanced ECG diagnostics, utilizing deep learning technology to deliver precise and scalable cardiac diagnostic solutions for healthcare providers and developers. Founded in 2020 in Belfast, Ireland, PulseAI focuses on integrating AI technology into ECG diagnostics. The company has completed one deal, with its most recent funding round occurring on January 12, 2026.

PulseAI was established by a team of innovators committed to enhancing cardiac care through technological advancements. Dr Alan Kennedy founded the firm and leading it as CEO as of 2026. PulseAI specializes in advanced ECG diagnostics powered by deep learning technology, focusing on delivering accurate, accessible, and scalable cardiac diagnostic solutions. Their core product offering includes an API designed for seamless integration into various healthcare applications, enabling developers and healthcare providers to leverage AI-driven ECG analysis for early heart disease detection.

This technology aims to enhance patient outcomes by providing timely diagnostics to healthcare professionals, thereby facilitating rapid intervention in critical cases. PulseAI's solutions serve a diverse clientele, including hospitals, healthcare providers, and technology companies across North America and Europe, thus broadening the reach of their innovative ECG software. The company’s products are tailored for integration into both consumer and enterprise-level applications, enhancing the capabilities of existing healthcare infrastructures. PulseAI's revenue model is structured around B2B partnerships and direct-to-consumer sales, primarily through subscription-based services for their API and on-device algorithms.

Clients typically engage with PulseAI through annual contracts that grant access to their suite of ECG analytics tools, allowing for scalable deployment within their existing systems. The pricing structure is designed to accommodate varying levels of usage, with tiered subscription plans reflecting the scope of services utilized by healthcare providers. The company’s flagship offerings focus on delivering deep learning insights and real-time diagnostic capabilities, supporting their clients in improving cardiac care. The robust transactional framework ensures a reliable stream of revenue as healthcare organizations increasingly adopt AI-driven solutions for enhanced patient care.

In January 2026, PulseAI Ltd. raised an undisclosed amount in Seed funding led by Innovation Ulster with participation from The Francis Crick Institute and Mortara Group, LLC. The funding will be utilized to scale deployment of its AI-ECG technology, advance FDA 510(k) clearance, complete clinical validation, and integrate products for enterprise and OEM partners. Looking forward, PulseAI is set to enhance its product offerings and expand into new markets, although specific geographic regions for this expansion have yet to be disclosed.